Children's Mercy Kansas City

SHARE @ Children's Mercy
Research Days

GME Research Days 2019

May 15th, 12:15 PM - 12:30 PM

Methotrexate Polyglutamates and the Potential Role in Pediatric
Inflammatory Bowel Disease
Ryan Morrow
rpmorrow@cmh.edu

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/researchdays
Part of the Higher Education and Teaching Commons, Medical Education Commons, Pediatrics
Commons, and the Science and Mathematics Education Commons

Morrow, Ryan, "Methotrexate Polyglutamates and the Potential Role in Pediatric Inflammatory Bowel
Disease" (2019). Research Days. 11.
https://scholarlyexchange.childrensmercy.org/researchdays/GME_Research_Days_2019/
GME_Research_Days_three/11

This Oral Presentation is brought to you for free and open access by the CONFERENCES, EVENTS, GRAND ROUNDS
at SHARE @ Children's Mercy. It has been accepted for inclusion in Research Days by an authorized administrator
of SHARE @ Children's Mercy. For more information, please contact library@cmh.edu.

Methotrexate Polyglutamates and the Potential Role in Pediatric Inflammatory Bowel
Disease
Submitting/Presenting Author (must be a trainee): Ryan Morrow
Primary Email Address: rpmorrow@cmh.edu
X Resident/Psychology Intern
⎕ Fellow
Primary Mentor (one name only): Dr. Valentina Shaknovich
Other authors/contributors involved in project: Ashley Sherman, Mara Becker, Ryan Funk
IRB Number: 14100454
Describe role of Submitting/Presenting Trainee in this project (limit 150 words):
Performed a retrospective chart review of patients enrolled under the current IRB project.
Reviewed current literature in both Rheumatology and Gastroenterology with regards to use of
methotrexate polyglutamates as a tool for therapeutic response, therapeutic drug monitoring, and
drug compliance. Participated in data analysis and interpretation and preparation of the
manuscript stemming from this work. Next steps include writing a research protocol for a larger,
longitudinal study aimed at investigating the role of methotrexate polyglutamates monitoring in
treatment response to methotrexate therapy in IBD.
Background, Objectives/Goal, Methods/Design, Results, Conclusions limited to 500 words
Background:
Methotrexate (MTX) is an immunomodulator used for the treatment of inflammatory bowel disease
(IBD). Inside the cell, methotrexate undergoes addition of glutamic acids to form methotrexate
polyglutamates (MTX-Glu), classified based on the length of the glutamate side-chain as MTX-Glu1
through 6. MTX-Glu show promise as potential biomarkers of systemic exposure to MTX and may have
clinical utility for prediction of therapeutic response, therapeutic drug monitoring, and dose
titration.
Objectives/Goal:
The clinical utility of MTX-Glu is being explored in adult rheumatology and gastroenterology
literature, with sparse information in children and no information in children with IBD. This gap in
knowledge is problematic as methotrexate is becoming a more widely-used immunomodulator in
the treatment of pediatric IBD. Our goal was to assess the relationship between MTX-Glu and
therapeutic response in children receiving MTX for IBD.
Methods/Design:
Cross sectional study of 21 children (5-21 years; 90% Crohn’s disease) receiving maintenance
therapy with infliximab (IFX) and MTX (i.e., no changes in dose or interval of either drug for ≥2 IFX

infusion cycles). At the time of MTX-Glu assessment, via measurement of erythrocyte MTX-Glu1-6
concentrations by HPLC/MS, IFX concentrations were measured by an established gene-reporter
assay (ARUP Laboratories) and disease activity (Remission vs. Active) determined by agreement on
Physician Global Assessment by two pediatric gastroenterologists. Given variability in clinical
dosing and age and size of children enrolled, all data were adjusted (adj) for mg/kg and interval
since drug received. Spearman’s correlation (ρ), Wilcoxon Rank Sum tests and multivariable
logistic regression analysis were used to compare parameters of interest in children with
Remission vs. Active disease (SAS; α=0.05); data reported as Median (IQR), unless otherwise
specified.
Results:
MTX doses ranged 5-25mg weekly (81% oral) and, as expected, MTX Glutot positively correlated
with mg/kg MTX received (ρ=0.5, p=0.02). adjMTX-Glutot was significantly higher in Remission
(n=11) vs. Active (n=10); 211 (126, 299) vs. 126 (62, 212), p=0.04. Short chain adjMTX-Glu1 103
(47, 120) vs. 37 (0, 50) and adjMTX-Glu2 60 (29, 72) vs. 24 (13, 38) were also significantly higher
(p=0.01 and 0.02, respectively) in Remission vs. Active. Although differences in IFX trough (p=0.4)
and adjtrough (p=0.25) were not statistically significant in Remission vs. Active disease, even after
incorporating adjtrough into a multivariable logistic regression model, the differences in adjMTXGlu1 (p=0.03) and adjMTX-Glu2 (p=0.04) remained significant between study groups. The two study
groups were comparable for age 16.0 (13.0, 17.0) vs. 14.5 (9.0, 19.5) and disease duration 2.5 (1.8,
5.2) vs. 3.8 (1.0, 4.7); both p=0.9.
Conclusions:
Total methotrexate polyglutamate levels correlate with MTX dose and appear to reflect systemic
MTX exposure. Total and short chain MTX-Glu were significantly higher in patients with disease
remission, independent of patient age, disease duration, or concomitant IFX therapy. These results
demonstrate a potential role for MTX-Glu as markers of disease response to MTX. Although the
cross-sectional design and small sample size in the present study could not identify minimum MTXGlu levels associated with therapeutic response, larger longitudinal studies may identify a
meaningful threshold for MTX therapeutic drug monitoring.

